Please enable Javascript
mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Low PNI May Indicate Poor Treatment Response in Patients With mHSPC Undergoing ADT
Emily Menendez
mHSPC
|
September 13, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Read More
mHSPC With Suboptimal PSA Response Linked to Poor Survival Outcomes
Emily Menendez
mHSPC
|
August 11, 2023
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Read More
How Does Performance Status Affect the Efficacy of Systemic Therapy for Prostate Cancer?
Emily Menendez
Prostate Cancer
|
August 2, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Read More
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
Emily Menendez
Prostate Cancer
|
June 20, 2023
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Read More
CHAARTED Trial Post Hoc Analysis Reveals QOL and Survival Outcomes
Emily Menendez
ASCO 2023
|
June 3, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Read More
Use of ARATs as First-line mHSPC Treatment Grows, NLR and PSA Serve as Prognostic Factors
Emily Menendez
mHSPC
|
May 18, 2023
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
Read More
Incidence of Clinical Fracture in mHSPC: Zoledronic Acid, Docetaxel, or Both?
Emily Menendez
AUA 2023
|
April 28, 2023
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Read More
Radiation’s Role in Metastatic Prostate Cancer Growing, Evolving
Leah Lawrence
Prostate Cancer
|
April 19, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Read More
ENZAMET Trial OS Analysis: Testosterone Suppression Plus Enzalutamide or Antiandrogen Therapy
Emily Menendez
mHSPC
|
April 14, 2023
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide.
Read More
Maha Hussain on the ARASENS Trial: Darolutamide Plus ADT, Docetaxel for mHSPC
Emily Menendez
Expert Interviews
|
March 30, 2023
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Read More
Evaluating MDT Without ADT in Patients With Solitary Oligorecurrent Prostate Cancer
David Ambinder, MD
mHSPC
|
February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Read More
Assessing Utilization Patterns of mHSPC Treatment in a Community Oncology Practice Setting
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Read More
Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings
Tanya Dorff, MD
mHSPC
|
February 13, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
View More
The Future of Personalized Care in Oligometastatic Prostate Cancer
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
View More
High-Risk Mutations in Oligometastatic Prostate Cancer Patients
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
View More
PSMA Imaging in Oligometastatic Prostate Cancer
Matthew Deek, MD
Next-Generation Imaging
|
January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
View More
MDT in omCSPC in the ORIOLE and STOMP Trials
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
View More
Safety and Efficacy of PSMA-RLT in Early-Stage and Hormone-Sensitive Prostate Cancer
Emily Menendez
RLT-PSMA
|
January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Read More
Circulating Tumor Cells May Predict Docetaxel Response in CRPC and mHSPC
Emily Menendez
mCRPC
|
January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Read More
Serum Testosterone-Measuring Assay Predicts Response to Castration in mHSPC
Zachary Bessette
mHSPC
|
December 7, 2022
High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict castration response.
Read More
Load More
Advertisement
Advertisement
Advertisement